In this study, we investigated the effects of oral treatments of E. multilocularis infected mice 23 with the anti-malarial drug mefloquine, and identified proteins that bind to mefloquine in 24 parasite extracts and human cells by affinity chromatography. In a pilot experiment, 25 mefloquine treatment was applied 5 days per week and intensified by stepwise increasing the 26 dosage from 12.5mg/kg to 200mg/kg during 4 weeks followed by treatments of 100mg/kg 27 during the last 7 weeks. This resulted in a highly significant reduction of parasite weight in 28 mefloquine-treated mice compared to mock-treated mice, but the reduction was significantly 29 less efficacious as compared to the standard treatment regimen with albendazole. In a second 30 experiment, mefloquine was orally applied in three different treatment groups at dosages of 31 25, 50 or 100mg/kg, but only twice a week, for a period of 12 weeks. Treatment at 100mg/kg 32 had a profound impact on the parasite, similar to albendazole treatment at 200mg/kg/day (5 33 days/week for 12 weeks). No adverse side effects were noted. In order to identify proteins in 34 E. multilocularis metacestodes that physically interact with mefloquine, we performed affinity 35 chromatography of metacestode extracts on mefloquine coupled to epoxy-activated sepharose, 36 followed by SDS-PAGE and in-gel digestion/LC-MS/MS. This resulted in the identification 37 of E. multilocularis ferritin and cystatin as mefloquine-binding proteins. In contrast, when 38 human cells were exposed to mefloquine-affinity chromatography, nicotinamide 39 
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Taeniidae. The life cycle of E. multilocularis is based on a predator-prey relationship. The 48 definitive hosts are wild carnivores such as the red fox (Vulpes vulpes) and the arctic fox 49 (Alopex lagopus), but the tapeworm also infects, and develops within the intestine of, 50 domestic dogs and cats, increasing the infection pressure for humans [1, 2] . The definitive 51 hosts shed eggs, which contain a first larval stage, the oncosphere. When taken up orally, 52 oncospheres hatch as they reach the intestine, penetrate the intestinal wall and use the blood 53 and lymphatic system for dissemination. They typically invade the liver, where they develop 54 into the the metacestode stage, which causes human alveolar echinococcosis (AE). AE is 55 distributed in the Northern hemisphere, the endemic areas stretching from Northern America 56 through Central and Eastern Europe to Central and East Asia including Northern parts of 57 Japan [1] . The increase in the urban fox populations in Central Europe, together with the high 58 prevalence rate of E. multilocularis in foxes, has resulted in an increased environmental 59 contamination with Echinococcus eggs, and as a consequence, this has led to an increased risk 60 of transmission to humans [2] . 61 Human AE manifests itself by tumor-like, infiltrative growth of metacestodes mainly in the 62 liver, but other organs might also be affected. AE is often compared with a slow-growing 63 liver cancer and if untreated the disease is usually lethal. The current strategy for treatment 64 consists of surgical measures complemented by chemotherapy with mebendazole (MBZ) or 65 albendazole (ABZ)). In inoperable cases, chemotherapy has proven to inhibit parasite 66 proliferation acting parasitostatic, but benzimidazoles act rarely curative, resulting in life-long 67 duration of treatment, high costs and elevated risk of side effects washed with distilled water and sedimented, followed by a two-step wash with coupling 143 buffer (100mM NaHCO 3 , pH 9.5). 20mg of MEF-HCl, solubilised in 1 ml DMSO, was added 144 to 1ml of the washed epoxy-sepharose matrix and incubated for 72h on a a slow horizontal 145 shaker at 37°C for 3 days in order to allow coupling to the epoxy-group. The resulting matrix 146 was then transferred to a chromatography column (Novagen, Merck, Darmstadt, Germany) 147 and washed with 20ml coupling buffer, followed by 1M ethanolamine pH 9.5 for 4h at room 148 temperature in the absence of light, in order to block residual groups. Subsequently, the7 column was extensively washed with PBS and PBS/DMSO (1:2) in order to remove unbound 150 mefloquine. In additon to the MEF-sepharose column a mock-column was prepared 151 containing epoxy-sepharose treated identically as described above but in the absence of MEF. 152
The columns were stored in PBS containing 0.02% NaN 3 at 4°C. (Fig. 1B) . The reduction in parasite 222 burden was a significant in the ABZ-treated group (p=0.018) and in the MEF (100mg/kg) 223 treated mice (p=0.018), while MEF treatment at lower doses (25 and 50mg/kg) showed a non-224 significant reduction. None of these drug treatments acted parasiticidal, since in vitro culture 225 of parasite material from all the treatment groups resulted in regrowth of metacestode 226 vesicles.
228
Epoxy-sepharose-immoblilized MEF binds E. multilocularis ferritin and cystatin. In 229 order to identify proteins that interact with MEF, E. multilocularis metacestode fractions were 230 exposed to sepharose-bound MEF. The fractions eluted from the mock-sepharose and the 231 MEF-sepharose columns were analyzed by SDS-PAGE and silver staining (Fig. 2) . After 232 loading E. multilocularis extract onto the mock-sepharose and subsequent MEF affinity 233 chromatography of the flow-through, the columns were washed with MEF-containing elution 234 buffer and subsequently with low pH buffer. As seen in Fig. 2 , washing of the mock-235 sepharose column with MEF-containing elution buffer did not result in removal of any 236
proteins. The elution with low pH-buffer revealed that considerable amounts of E. 237 multilocularis proteins bound to the sepharose matrix and were released again at low pH. 238 MEF-sepharose affinity chromatography of the mock-sepharose-flow-through fraction 239 yielded a major double-protein band of around 20kDa eluting with MEF-containing buffer. 240 Subsequent washing with low-pH buffer did not result in further release of proteins (Fig. 2) . 241
The two bands of the MEF elution (indicated with arrows as 1 and 2, (Fig. 3) . The 50kDa band was subjected to analysis by mass 254 spectrometry and identified as the 491 amino acid protein nicotinamide-phosphoribosyl-255 transferase (NAPRT; P43490). 256 257 DISCUSSION 258
259
As the pilot study showed, a stepwise increase of oral MEF input was significantly effective, 260 but had detrimental effects, resulting in a lower efficacy of MEF compared to ABZ, and 261 obvious adverse side effects once higher concentrations than 100mg/kg were applied. 262
The second study demonstrates that oral application of mefloquine at 100mg/kg twice a week 263 for 12 weeks in experimentally infected mice acts against E. multilocularis metacestodes in a 264 similar manner as oral application of albendazole (200mg/kg/ on 5 days per week). 265
Mefloquine applied at 25mg/kg or 50mg/kg was ineffective, confirming results from earlier 266 studies [9] . At the lower concentrations the bioavailability of MEF was probably too low to 267 elicit a therapeutically active serum level, while an increased MEF input resulted in serum 268 levels that induced toxicity. For comparison, high single oral MEF doses of 200 to 400mg/kg 269 were necessary to achieve significant worm burden reductions in S. mansoni-and S. 270 japonicum-infected mice. However, for extended treatments (as they would be anticipated in 271 AE patients), the application of MEF could be problematic. Daily doses above 12.5mg/kg 272 have been reported to cause epilepsy or impairment of motor performance, and increased 273 lethality was observed in mice at dosages of 30mg/kg and more [14] [15] [16] [17] [18] . Despite of the 274 reported adverse effects of MEF when applied in high doses [18] , no adverse effects were 275 observed in the behavior or overall health of the animals throughout the treatment phase in 276 experiment 2, most likely due to the fact that treatments were restricted to twice a week. In 277 any case, this study shows the critical role of dosage to achieve anti-parasitic activity without 278 causing adverse effects. Further it has to be highlighted that unlike shown in a previous in12 vitro study [9] , in vivo MEF treatment did not kill the parasite completely. Full parasiticidal 280 activity, and especially toxic activity against E. multilocularis stem cells, would be necessary 281 to completely kill the parasite and avoid the necessity of life-long drug uptake [19] . 282
Research on novel compounds for the treatment of secondary AE in mice should focus on 283 drugs or drug classes that are already marketed and/or in clinical development, and these are 284 preferably cancer drugs or broad-spectrum anti-parasitic compounds. In this respect, MEF is 285 commercially available, FDA-approved, and has been extensively characterized in terms of 286 bioavailability, pharmacokinetics, and toxicity. However, the adverse effects reported upon 287 the uptake of MEF are a problematic issue. The drug is known to cause neurotoxicity, and 288 neuropsychiatric effects have been reported. Thus, it would be important to further investigate 289 derivatives of MEF, and identify those compounds with similar anti-parasitic activity but with 290 an impaired ability to pass through the blood-brain barrier. In addition, it has been shown that 291 MEF is metabolized only slowly, with a plasma half-life in humans of 2-4 weeks, and 292 metabolization occurs in the liver. During long-term treatments, as they would be anticipated 293 in human patients suffering from AE, which represents mainly a liver-associated disease, this 294 could cause significant adverse effects. 295
296
The interaction of E. multilocularis ferritin and cystatin with MEF by affinity 297 chromatography could indicate a possible anti-echinococcal mechanism of action for the drug. 
